Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

2.50
Hdl Handle:
http://hdl.handle.net/10541/76519
Title:
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Authors:
Thatcher, Nick; Chang, Alex; Parikh, Purvish; Rodrigues Pereira, José; Ciuleanu, Tudor; Von Pawel, J; Thongprasert, Sumitra; Tan, Eng Huat; Pemberton, Kristine; Archer, Venice; Carroll, Kevin
Abstract:
BACKGROUND: This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer. METHODS: 1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care. The primary endpoint was survival in the overall population of patients and those with adenocarcinoma. The primary analysis of the population for survival was by intention to treat. This study has been submitted for registration with ClinicalTrials.gov, number 1839IL/709. FINDINGS: 1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7.2 months, median survival did not differ significantly between the groups in the overall population (5.6 months for gefitinib and 5.1 months for placebo; hazard ratio 0.89 [95% CI 0.77-1.02], p=0.087) or among the 812 patients with adenocarcinoma (6.3 months vs 5.4 months; 0.84 [0.68-1.03], p=0.089). Preplanned subgroup analyses showed significantly longer survival in the gefitinib group than the placebo group for never-smokers (n=375; 0.67 [0.49-0.92], p=0.012; median survival 8.9 vs 6.1 months) and patients of Asian origin (n=342; 0.66 [0.48-0.91], p=0.01; median survival 9.5 vs 5.5 months). Gefitinib was well tolerated, as in previous studies. INTERPRETATION: Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population. There was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.
Affiliation:
Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. nick.thatcher@christie-tr.nwest.nhs.uk
Citation:
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)., 366 (9496):1527-37 Lancet
Journal:
Lancet
Issue Date:
6-Aug-2009
URI:
http://hdl.handle.net/10541/76519
DOI:
10.1016/S0140-6736(05)67625-8
PubMed ID:
16257339
Type:
Article
Language:
en
ISSN:
1474-547X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nick-
dc.contributor.authorChang, Alex-
dc.contributor.authorParikh, Purvish-
dc.contributor.authorRodrigues Pereira, José-
dc.contributor.authorCiuleanu, Tudor-
dc.contributor.authorVon Pawel, J-
dc.contributor.authorThongprasert, Sumitra-
dc.contributor.authorTan, Eng Huat-
dc.contributor.authorPemberton, Kristine-
dc.contributor.authorArcher, Venice-
dc.contributor.authorCarroll, Kevin-
dc.date.accessioned2009-08-06T14:06:12Z-
dc.date.available2009-08-06T14:06:12Z-
dc.date.issued2009-08-06T14:06:12Z-
dc.identifier.citationGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)., 366 (9496):1527-37 Lanceten
dc.identifier.issn1474-547X-
dc.identifier.pmid16257339-
dc.identifier.doi10.1016/S0140-6736(05)67625-8-
dc.identifier.urihttp://hdl.handle.net/10541/76519-
dc.description.abstractBACKGROUND: This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer. METHODS: 1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care. The primary endpoint was survival in the overall population of patients and those with adenocarcinoma. The primary analysis of the population for survival was by intention to treat. This study has been submitted for registration with ClinicalTrials.gov, number 1839IL/709. FINDINGS: 1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7.2 months, median survival did not differ significantly between the groups in the overall population (5.6 months for gefitinib and 5.1 months for placebo; hazard ratio 0.89 [95% CI 0.77-1.02], p=0.087) or among the 812 patients with adenocarcinoma (6.3 months vs 5.4 months; 0.84 [0.68-1.03], p=0.089). Preplanned subgroup analyses showed significantly longer survival in the gefitinib group than the placebo group for never-smokers (n=375; 0.67 [0.49-0.92], p=0.012; median survival 8.9 vs 6.1 months) and patients of Asian origin (n=342; 0.66 [0.48-0.91], p=0.01; median survival 9.5 vs 5.5 months). Gefitinib was well tolerated, as in previous studies. INTERPRETATION: Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population. There was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshQuinazolines-
dc.subject.meshSurvival Rate-
dc.titleGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).en
dc.typeArticleen
dc.contributor.departmentMedical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. nick.thatcher@christie-tr.nwest.nhs.uken
dc.identifier.journalLanceten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.